Health Condition 1: J984- Other disorders of lung
Conditions
Interventions
Intervention1: NEBULIZATION WITH TRANEXAMIC ACID BEFORE STARTING ENDOBRONCHIAL BIOPSIES: intervention group subjects will be nebulised with tranexamic acid at a dose of 500mg(5ml)
of intravenous formu
Sponsors
PGIMS ROHTAK
Eligibility
Inclusion criteria
Inclusion criteria: All patients aged =18 years posted for fiberoptic bronchoscopy with a plan for obtaining endobronchial biopsy.
Exclusion criteria
Exclusion criteria: 1) Active and ongoing pulmonary bleeding (haemoptysis), 2) Known history of bleeding predisposition, 3) Decompensated liver disease, 4) Kidney disease (an estimated glomerular filtration rate of =30 ml/min), 5) Known allergy to tranexamic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of nebulized tranexamic acid in increasing the adequacy of endobronchial biopsy.Timepoint: Adequate sample will be defined as biopsy sample sufficient for histopathology, immunohistochemistry, and molecular analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the efficacy to control bleeding during endobronchial biopsy.Timepoint: Severity of bleeding: Mild: requiring continuous suctioning and bleeding stopped spontaneously. Moderate: requiring use of cold saline or epinephrine to control bleeding. Severe: placement of bronchial blocker /balloon catheter/ applying fibrin sealant, fluid resuscitation/ blood transfusion, admission to critical care unit or death.;To assess the number and size of biopsies obtained.Timepoint: Number of biopsies will be determined based upon successful passes taken and size will be compared with the cup of the forceps, small- cup is bigger than tissue,Medium- tissue fills the cup, large- tissue is largen than the cup;To assess the procedure length.Timepoint: Length of the procedure from nebulization with study agent to end of the procedure. Length of the procedure as assessed from introduction of scope to the end of the procedure.;To assess the safety of nebulized tranexamic acid just prior to endobronchial biopsy.Timepoint: Incidence and frequency all adverse events and SAEs will be reported as per the CTCAE Version 5.0. | — |
Countries
India
Contacts
Public ContactVineela Surapaneni
Pandit B.D Sharma, PGIMS, Rohtak
Outcome results
None listed